Javascript must be enabled to continue!
Brief of Law Professors Joshua D. Sarnoff, Sharon K. Sandeen, and Ana Santos Rutschman as Amici Curiae in Support of Respondents, Amgen, Inc. V. Sanofi, No. 21-757
View through CrossRef
For over two hundred years, the Patent Act has consistently required that an applicant for a patent actually conceive an invention and disclose what they have invented, in a manner that also enables skilled practitioners to make and use the invention conceived and disclosed. Courts have applied many different doctrines to invalidate patents or patent claims when applicants have sought to patent what they have not invented or disclosed, typically by claiming results or by claiming a genus of unenumerated structures that perform desired results or recited functions. Courts have made clear that such claims are not claims to “inventions” within the meaning of the Patent Act, because the applicants have not yet determined what structures would perform the desired or recited functions. Such invalid claims, where the applicant has failed to disclose a sufficient structural-functional relationship, have variously been referred to as not invented, overbroad, functional at the point of novelty, research plans, or not enabled.<br><br>Under the enablement doctrine, applicants: (1) cannot shift to the public the burden of “inventing” the claimed genus; and (2) must provide sufficient information for the public to “make and use” a properly disclosed and claimed genus invention. Although the decision of the U.S. Court of Appeals for the Federal Circuit in this case was clearly correct under In re Wands, 858 F.2d 731 (Fed. Cir. 1988), this Court needs to provide guidance on both aspects of the enablement standard in order to support its further refinement. First, how much of a structural-functional relationship must be disclosed to validly support a genus claim without improperly shifting the burden of inventing to skilled artisans? Second, for an already invented and properly disclosed genus, how much additional information must an applicant provide to “enable” skilled artisans to “make and use” the claimed genus? This second requirement must consider how much time, money, and effort can be imposed by applicants on skilled practitioners in regard to the scope of the invention actually claimed. The current “undue experimentation” standard in Wands, however, does not provide any meaningful referent to guide such analysis (“undue” compared to what?), and improperly conflates these two required inquiries. Nevertheless, the evidentiary factors identified in Wands remain relevant to the second inquiry.<br><br>This Court and the Federal Circuit have identified numerous concerns underlying the various patent law doctrines that prohibit claiming a genus of structures without disclosing a sufficient structural-functional relationship. In general, there are two important reasons not to permit such claims. The first is that granting such claims provides a disproportionate reward to applicants. Applicants are entitled to claim the particular structural species that they have identified that perform the desired functions. When they do so, applicants then may receive additional protection for functionally “equivalent” structures under the “doctrine of equivalents.” If applicants also can identify a common structural-functional relationship that sufficiently assures that other structures will perform the required functions, then (and only then) can they validly claim a genus of structures that they have not identified individually. This assures commensurability between the invention made and the rights granted. The second reason is that claiming a result or a research plan blocks sequential innovation and commercialization of additional structures that the applicant has not yet identified to possess the desired result or recited function, but has claimed using structural or functional language. This excessive claiming is particularly pernicious given the constrained experimental use exception adopted by the lower courts.<br><br>The instant case is an “easy case” in view of the complete lack of disclosure connecting structure to function. The case involves broad genus claims based entirely on desired and claimed functions. There is no disclosure that would indicate what structures are even likely to exhibit the recited functions, while requiring structures falling within the claimed genus to do so. This case thus does not require the Court to address how much of a structural-functional relationship must be identified and disclosed in order to invent, disclose, and properly claim a genus. Nor does this case require the Court to address the permissible amount of time, effort, and money that can be required of skilled practitioners to make and use a properly disclosed and claimed genus. The Court thus should affirm the decision below and invalidate the claims at issue without remand, while providing the required guidance for the lower courts to further develop the law of enablement.
Title: Brief of Law Professors Joshua D. Sarnoff, Sharon K. Sandeen, and Ana Santos Rutschman as Amici Curiae in Support of Respondents, Amgen, Inc. V. Sanofi, No. 21-757
Description:
For over two hundred years, the Patent Act has consistently required that an applicant for a patent actually conceive an invention and disclose what they have invented, in a manner that also enables skilled practitioners to make and use the invention conceived and disclosed.
Courts have applied many different doctrines to invalidate patents or patent claims when applicants have sought to patent what they have not invented or disclosed, typically by claiming results or by claiming a genus of unenumerated structures that perform desired results or recited functions.
Courts have made clear that such claims are not claims to “inventions” within the meaning of the Patent Act, because the applicants have not yet determined what structures would perform the desired or recited functions.
Such invalid claims, where the applicant has failed to disclose a sufficient structural-functional relationship, have variously been referred to as not invented, overbroad, functional at the point of novelty, research plans, or not enabled.
<br><br>Under the enablement doctrine, applicants: (1) cannot shift to the public the burden of “inventing” the claimed genus; and (2) must provide sufficient information for the public to “make and use” a properly disclosed and claimed genus invention.
Although the decision of the U.
S.
Court of Appeals for the Federal Circuit in this case was clearly correct under In re Wands, 858 F.
2d 731 (Fed.
Cir.
1988), this Court needs to provide guidance on both aspects of the enablement standard in order to support its further refinement.
First, how much of a structural-functional relationship must be disclosed to validly support a genus claim without improperly shifting the burden of inventing to skilled artisans? Second, for an already invented and properly disclosed genus, how much additional information must an applicant provide to “enable” skilled artisans to “make and use” the claimed genus? This second requirement must consider how much time, money, and effort can be imposed by applicants on skilled practitioners in regard to the scope of the invention actually claimed.
The current “undue experimentation” standard in Wands, however, does not provide any meaningful referent to guide such analysis (“undue” compared to what?), and improperly conflates these two required inquiries.
Nevertheless, the evidentiary factors identified in Wands remain relevant to the second inquiry.
<br><br>This Court and the Federal Circuit have identified numerous concerns underlying the various patent law doctrines that prohibit claiming a genus of structures without disclosing a sufficient structural-functional relationship.
In general, there are two important reasons not to permit such claims.
The first is that granting such claims provides a disproportionate reward to applicants.
Applicants are entitled to claim the particular structural species that they have identified that perform the desired functions.
When they do so, applicants then may receive additional protection for functionally “equivalent” structures under the “doctrine of equivalents.
” If applicants also can identify a common structural-functional relationship that sufficiently assures that other structures will perform the required functions, then (and only then) can they validly claim a genus of structures that they have not identified individually.
This assures commensurability between the invention made and the rights granted.
The second reason is that claiming a result or a research plan blocks sequential innovation and commercialization of additional structures that the applicant has not yet identified to possess the desired result or recited function, but has claimed using structural or functional language.
This excessive claiming is particularly pernicious given the constrained experimental use exception adopted by the lower courts.
<br><br>The instant case is an “easy case” in view of the complete lack of disclosure connecting structure to function.
The case involves broad genus claims based entirely on desired and claimed functions.
There is no disclosure that would indicate what structures are even likely to exhibit the recited functions, while requiring structures falling within the claimed genus to do so.
This case thus does not require the Court to address how much of a structural-functional relationship must be identified and disclosed in order to invent, disclose, and properly claim a genus.
Nor does this case require the Court to address the permissible amount of time, effort, and money that can be required of skilled practitioners to make and use a properly disclosed and claimed genus.
The Court thus should affirm the decision below and invalidate the claims at issue without remand, while providing the required guidance for the lower courts to further develop the law of enablement.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Pengaruh Amicus Curiae (Sahabat Pengadilan) dalam Mempengaruhi Putusan Hakim menurut Sistem Peradilan Pidana
Pengaruh Amicus Curiae (Sahabat Pengadilan) dalam Mempengaruhi Putusan Hakim menurut Sistem Peradilan Pidana
Abstract. This research focuses on the regulation of Amicus Curiae in criminal procedural law in Indonesia and the influence of Amicus Curiae on judges' decisions in criminal justi...
105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial
105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial
Background: InRange has previously demonstrated that insulin glargine 300 U/mL (Gla-300) is non-inferior to insulin degludec 100 U/mL (IDeg-100) in terms of time in glucose range 7...
P0672 Persistence of Vedolizumab after switching to the subcutaneous route: results from the national French cohort study DOPER
P0672 Persistence of Vedolizumab after switching to the subcutaneous route: results from the national French cohort study DOPER
Abstract
Background
Vedolizumab (VDZ) has been available in France as a subcutaneous formulation for the treatment of inf...
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Insulin in T2D is associated with hypoglycemia and weight gain, requires training, can be expensive, and is generally not preferred by patients. Reducing insulin needs is attractiv...

